Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of the fixed combination of
pyronaridine artesunate (Pyramax®, PA) (180:60 mg) with that of standard chloroquine therapy
in children and adults with acute, uncomplicated Plasmodium vivax malaria.